Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Receivables: 2020-2024

  • Janux Therapeutics' Change in Receivables rose 1030.80% to $7.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of -$8.0 million for FY2021, which is 200.00% down from last year.
  • According to the latest figures from Q2 2024, Janux Therapeutics' Change in Receivables is $7.0 million, which was up 1,245.09% from $519,000 recorded in Q1 2024.
  • Over the past 5 years, Janux Therapeutics' Change in Receivables peaked at $8.0 million during Q4 2020, and registered a low of -$7.6 million during Q1 2021.
  • For the 3-year period, Janux Therapeutics' Change in Receivables averaged around $1.2 million, with its median value being $509,500 (2022).
  • The largest annual percentage gain for Janux Therapeutics' Change in Receivables in the last 5 years was 1,030.80% (2024), contrasted with its biggest fall of 30.80% (2024).
  • Over the past 5 years, Janux Therapeutics' Change in Receivables (Quarterly) stood at $8.0 million in 2020, then reached -$375,000 in 2021, then soared by 233.33% to -$500,000 in 2022, then reached -$750,000 in 2023, then soared by 1,030.80% to $7.0 million in 2024.
  • Its last three reported values are $7.0 million in Q2 2024, $519,000 for Q1 2024, and -$750,000 during Q2 2023.